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Abstract
Biallelic loss-of-function mutations in TYROBP and TREM2 cause a rare disease that
resembles early-onset frontotemporal dementia with bone lesions (PLOSL). Some PLOSL-
causing variants in TREM2 have also been associated with Alzheimer’s disease when
heterozygous. Here, we studied the PLOSLFIN TYROBP deletion that covers four of the gene’s
five exons. We genotyped 3220 older Finns (mean age 79, range 58-104) and found 11 deletion
carriers (mean age 78, range 60-94). The carrier prevalence was 0.0034 (1 in 293) that
matches previous findings in younger cohorts suggesting no significant early mortality. By
comparing MMSE scores and diagnoses of dementia we did not find any significant
differences between TYROBP deletion carriers and non-carriers (all p-values >0.5).
Neuropathological analysis of two deletion carriers (aged 89 and 94) demonstrated only
minimal beta-amyloid pathology (CERAD score 0). Collectively these results suggest that
heterozygous carriership of the TYROBP deletion is not a major risk factor of cognitive
impairment.
Highlights: 3-5 bullet points
∑ Loss-of-function mutations in TYROBP and TREM2 cause early-onset frontotemporal
dementia with bone lesions (PLOSL)
∑ TREM2 and TYROBP are part of the same receptor-signaling complex
∑ Heterozygous variants in TREM2 are risk factors for neurodegenerative diseases
∑ The PLOSLFIN deletion of TYROBP is not a strong risk factor for cognitive impairment
when heterozygous
Keywords
Genetics; Alzheimer’s disease; Dementia; TYROBP; DAP12; PLOSL
1. Introduction
Triggering receptor expressed on myeloid cells 2 (TREM2) and TYRO protein tyrosine kinase
binding protein (TYROBP) are part of the same receptor-signaling complex (Paloneva et al., 2002).
Biallelic loss-of-function mutations in TYROBP or TREM2 genes cause polycystic lipomembranous
osteodysplasia with sclerosing leukoencephalopathy (PLOSL, Nasu-Hakola disease) (Paloneva et
al., 2000, Paloneva et al., 2002), a rare disease characterized by pathologic fractures, personality
changes and presenile dementia (Hakola, 1972). In TYROBP, also known as DAP12, compound
heterozygous mutations have been reported to cause PLOSL (Kuroda et al., 2007) whereas
compound heterozygous mutations in TREM2 also lead to a frontotemporal dementia –like
phenotype (Guerreiro et al., 2013). TREM2 and TYROBP have also been genetically or functionally
associated with Alzheimer’s disease (AD), both late-onset (LOAD) (Jonsson et al., 2013, Sims et
al., 2017, Zhang et al., 2013) and early-onset forms (Pottier et al., 2016, Slattery et al., 2014). While
the association of TREM2 and AD seems strong, less data on TYROBP is available and it is
inconclusive. However, a recent gene-regulatory network analysis of postmortem brains suggested
TYROBP as an important regulator of gene expression in Alzheimer’s disease (Zhang et al., 2013).
In a cohort of 103 Turkish patients with different forms of dementia (average age of onset <66.7
years) a TYROBP p.Val55Leu variant was found in three individuals, but this variant was not
considered pathogenic (Darwent et al., 2017).  In this article, we studied the effect of PLOSLFIN-
deletion of TYROBP on cognitive impairment.
In this study, we genotyped 3220 older Finns for the 5.3kb deletion in TYROBP that causes PLOSL
in individuals of Finnish ancestry (Paloneva et al., 2000) and found no association with cognitive
impairment.
2. Material and Methods
2.1. Cohorts
We studied four population-derived cohorts from the Finnish capital region (Helsinki area) from
whom the 5.3kb TYROBP PLOSLFIN -deletion was genotyped and information on cognition was
available. We also analyzed APOE alleles and APP p.Ala673Thr variant to compare the background
genetic risk burden for cognitive impairment between TYROPB deletion carriers and non-carriers.
APOE ε4 is the most prevalent genetic risk factor for cognitive impairment and APP p.Ala673Thr is
a strong protective mutation against Alzheimer’s disease and age-associated cognitive decline
(Jonsson et al., 2012, Kero et al., 2013).
The Helsinki Birth cohort study (HBCS) consists of 8760 individuals born in Helsinki in 1934-1944
(Barker et al., 2005, Eriksson et al., 2006). In 2001-2004, a random sample of 2003 individuals
participated in a clinical study including DNA extraction (Kajantie et al., 2012, Yliharsila et al.,
2007) and a random subsample’s cognition was assessed with MMSE and CERAD. In addition,
registry information up till December 31 of 2013 were checked for dementia hospitalizations and
dementia deaths. This included data on diagnoses of any organic dementias, given by physicians in
inpatient (1969-2013) and outpatient (1998-2013) care (codes 290.00-290.10 from International
Classification of Diseases (ICD)-8, 290, 2912A, 2928C, 2941A, 3310A and 3311A from ICD-9,
and F00, F01, F03, F051 and G30 from ICD-10) and of Alzheimer’s disease (codes 331.0 and 290.1
from ICD-9, and G30 and F00 from ICD-10) until December 31 of 2013 were derived from the
Finnish Hospital Discharge and Causes of Death Registers (Lahti et al., 2014).
Helsinki Businessmen Study (HBS) originally consists of 3,490 healthy Finnish men, born 1919-
1934. All participants were businessmen or executives with similar and high socioeconomic status.
In 2002-2003, 672 individuals who lived at home were randomly selected for analyses and 650 of
them gave a venous blood sample. Participants’ cognition was tested using the MMSE (Strandberg
et al., 2016). In 2014 cognition was evaluated with a questionnaire.
The DEBATE cohort consists of a random sample of 4,800 individuals living in Helsinki, Finland.
In 2000, 400 home-living individuals with stable cardiovascular disease (coronary artery disease,
stroke or transient ischemic attack, peripheral artery disease) were clinically examined and
cognitive functions were assessed with MMSE. (Uusvaara et al., 2013) In 2014 dementia diagnoses
were screened from death certificates.
Vantaa 85+ Study  includes 601 individuals, aged 85 years and older, who were living in the city of
Vantaa, Finland. 553 individuals underwent neurological examination including MMSE by two
neurologists in 1991-1992, with follow-up studies in 1994, 1996, 1999 and 2001.
Neuropathological autopsy was performed on 281 individuals (Polvikoski et al., 1995).
The study was approved by the Coordinating Ethics Committee of the Helsinki University Central
Hospital. The Vantaa 85+ study was also approved by the Ethics Committee of the Health Centre of
the City of Vantaa.
2.2. Genotyping
Genomic DNA was available of 3260 samples from the four different cohorts. Samples from
VV85+ were whole genome amplified DNA derived from peripheral blood leukocytes (PBLs).
DNA from other samples was derived from PBLs. We used PCR assay with one forward and two
reverse primers to genotype the samples. Samples without the deletion produce one amplicon
(~500bp), samples heterozygous for the deletion produce two amplicons(~500bp and ~700bp) and
samples homozygous for the deletion produce only the larger amplicon (~700bp). Primer sequences
were 5’ GGCCACATCCGTATGACTG 3’ for forward primer, 5’
TAGTATGTCCAGTCTCGAGTTCTCA 3’ for reverse primer 1 and 5’
CTAGTCTGGGCGTGCATTC 3’ for reverse primer 2. We used a positive control in all PCR
assays.
We performed PCR in 20 µl reactions containing 100ng of DNA, 0.50 µl of Dynazyme II DNA
polymerase (Thermo Scientific, Waltham, USA), 1.0 M Betaine (Affymetrix, Santa Clara, USA),
0.3 mM of dNTP (Thermo Scientific), 0.5 mM of each primer (Sigma-Aldrich, St.Louis, USA) and
1.0x optimized Dynazyme PCR buffer (Thermo scientific, Waltham, USA). PCR was started with
an initial denaturation at 94˚for 12 min; followed by 40 cycles of 30 sec at 94˚, 15 sec at 60˚ (-1˚ for
every cycle until at 55˚) and 30 sec at 72˚; and a final extension at 72˚ for 10 min. Amplicons were
visualized in 2% agarose gel electrophoresis with ethidium bromide to determine the genotype of
every sample.
APOE was genotyped as previously described (Myllykangas et al., 1999). APP p.Ala673Thr was
genotyped as previously described (Kero et al., 2013).
2.3. Assessment of cognitive impairment
In the first analysis, we analyzed MMSE scores as a dichotomized variable where people with an
MMSE score ≤24 were considered to have cognitive impairment. In the second analysis, MMSE
scores were treated as a continuous variable. In a third analysis, we used cohort-specific information
as complementary information. This information was, depending on cohort, a clinical diagnosis of
dementia, any dementia diagnosis on death certificate, a questionnaire study with self-reported
diagnoses and medications or hospital discharge and cause of death register information on any
dementia diagnosis. In this third analysis, individuals with MMSE scores ≤24 or who had any
diagnosis of dementia were considered to have cognitive impairment.
2.4. Statistical analyses
Analyses were conducted with SPSS v.24.0 (IBM Corp. Released 2016. IBM SPSS Statistics for
Windows, Version 24.0. Armonk, NY: IBM Corp.). We used Fisher’s exact test and Mann-Whitney
U test to test for the association between cognitive impairment and the deletion. We used the same
tests to study the differences in age, sex, APOE ε4 and APP p.Ala673Thr between deletion carriers
and non-carriers.
Statistical power was calculated with the Genetic Power Calculator
(http://zzz.bwh.harvard.edu/gpc/, accessed August 10, 2017) (Purcell et al., 2003). Assuming
deletion prevalence of 0.0034 based on our sequencing results, 20% prevalence of cognitive
impairment in ≥75 years old Finnish population (Rahkonen et al., 2003), relative risk of 2.5, case-
control ratio of 4 and α=0.05, 423 cases were required for 80% power. This number of cases was
achieved in all analyses.
3. Results
All cohorts together, we genotyped successfully 3220 (98.7%) individuals and 11 were
heterozygous for the deletion, giving a total frequency of 0.0034. DEBATE was the only cohort
with no deletion carriers (Supplementary Table1). No sample was homozygous for the deletion as
could be expected. A summary of the characteristics of the 11 deletion carriers is shown in
Supplementary Table2.
MMSE scores were available for 2390 individuals, including seven deletion carriers. In the first
analysis, 497 non-carriers (21%) and one deletion carrier (14%) had cognitive impairment (MMSE
≤24) (Fisher’s exact test p=1). When MMSE scores were analyzed as a continuous variable, there
was no significant difference between deletion carriers and non-carriers (Mann-Whitney U test
p=0.68). In the third analysis, any information on cognition (MMSE, questionnaire, diagnosis of
dementia) was retrieved from 3192 individuals including all 11 deletion carriers. Of the deletion
carriers, three (27%) and of the non-carriers 692 (22%) had cognitive impairment (Fisher’s exact
test p=0.71). In all three analyses there were no statistically significant differences between carriers
and non-carriers in age, sex, APP p.Ala673Thr or APOE ε4 status. In the first and second analyses,
deletion carriers vs. non-carriers had the following characteristics: mean age 77,9 vs. 76,1 years
(mean ranks 1350 vs 1195, p=0.55), 57.1 %  vs. 44,9% females (p=0.71) and 28.6 %  vs. 32,4 %
had the APOE ε4 allele (p=1.0). In the third analysis deletion carriers vs. non-carriers had the
following characteristics: mean age 77.6 vs. 78,9 years (mean ranks 1463 vs 1596 p=0.63), 54.5 %
vs. 46,7 % females (p=0.76) and 45.5% vs. 32.9 % (p=0.52) . There were 23 (0.7%) carriers of the
APP p.Ala673Thr variant, none among the TYROBP deletion carriers (p=1.0 in all analyses).
Two subjects of the Vantaa85+ study were autopsied at the ages of 89 and 94.Their mean
percentage of the cortex covered by methenamine silver-positive senile plaques in sections cut from
4 neocortical samples (neocortical beta-amyloid percentages) were 0% and m 0.18%, both had a
CERAD score of 0 and Braak stages 3 and 4.  These neuropathological features do not show
significant signs of AD pathology. The mean beta-amyloid percentages in the Vantaa85+
population were 3.4%, Braak stage 3.3 and CERAD 1.4 (in the Vantaa 85+ study: score 1= sparse
neuritic senile plaques, 2 = moderate frequency of neuritic senile plaques, 3= frequent neuritic
senile plaques).
We performed logistic regression analyses to study the effect of APOE ε2 and ε4 carriership on
cognitive impairment and used age and sex as covariates. APOE ε4 carriership associated with
cognitive impairment in both MMSE score -based analysis (p=2.3 x 10-4, OR 1.7 (1.3-2.3)) and
when all information available on cognition was used (p=2.4 x 10-9, OR=1.9 (1.5-2.4)). APOE ε2
associated with better cognition when using cognitive impairment status derived from MMSE
scores (p=0.019, OR=0.6 (0.39-0.92)) and showed a trend for better cognition when all information
available on cognition was used (p=0.07, OR=0.74 (0.54-1.03)).
4. Discussion
We used MMSE scores and dementia diagnoses to study cognitive impairment on PLOSLFIN
deletion carriers and non-carriers and found no statistically significant differences.
Neuropathological data on two deletion carriers brings additional support that the deletion is not a
major risk factor for Alzheimer’s disease. On the contrary, both had very low neocortical beta-
amyloid percentages and CERAD scores, which is noteworthy because it is known that TREM2 and
TYROBP expressing microglia accumulate around senile plaques but whether the effect is
beneficiary or harmful is still under debate.
To the best of our knowledge, we report the first data on cognition and neuropathological
examination of older individuals with a heterozygous PLOSL-causing TYROBP variant. Our results
suggest that the deletion is not a major risk factor for cognitive impairment. The main limitations of
our study arise from the rarity of the PLOSLFIN –deletion and larger studies are needed to exclude
minor effects on cognition. Moreover, it is not known how much TYROBP protein levels decrease
in the deletion carriers  since we were not able to study the expression level of TYROBP.
High socioeconomic status is also known to be a protective factor against cognitive impairment and
MMSE test may lose some of its sensitivity with highly-educated people. Unfortunately, we did not
know the socioeconomic status of most of the participants and could not include the effect of
socioeconomic status into our analyses.
The VV85+ samples were whole-genome amplified DNA whereas other samples were genomic
DNA extracted from blood. Amplification is a potential source of error when studying larger
deletions. In our study, however, the frequency of the studied deletion in the VV85+ samples was in
line with the other cohorts suggesting no error occurred during whole genome amplification.
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HBCS HBS VV85+ DEBATE Total
Total (n) 8760 3490 553 4821 17624
DNA available (n) 1680 672 531 377 3260
Successfully genotyped 1678 646 526 370 3220
Number of deletions (%) 6 (0.36) 3 (0.46) 2 (0.38) 0
11
(0.34)
MMSE available (n) 898 609 513 370 2390
mean age 68,1 75,7 88,5 80,1 76,3
SD of age 4,8 3,9 2,84 4,8 8,5
men (%) 40 100 20 65 55
MMSE/other info available
(n) 1678 619 525 370 3192
mean age 71,7 84,3 88,5 88,6 79
SD of age 3,2 4,9 2,84 4,8 8,6
men (%) 44 100 21 65 53
 Supplementary Table 1: Cohort information. First four rows show the number of individuals in the
four cohort studies, the number of individuals used in this study and the number of deletions found.
The fifth row shows the number of individuals whose MMSE scores were available. The ninth row
shows the number of individuals from which cognitive impairment status was known either from
MMSE scores or other information available.

Vantaa 85+ study Helsinki businessmen study Helsinki birth cohort study
1 2 3 4 5 6 7 8 9 10 11
Age at MMSE 89 85 74 79 82 68 68 - - - -

















































Died at 60 of
coronary disease
and pneumonia
Sex female female male male male female female male female male female
APOE e4 2/3 2/3 3/4 2/3 3/3 3/4 3/3 3/4 3/4 3/3 3/4
Supplementary Table 2. A summary of the characteristics of the 11 deletion carriers

